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Experimental Procedures 
General experimental details 
Commercially available reagents (Carl Roth GmbH and Co. KG, Karlsruhe, Germany; Sigma-Aldrich 
Taufkirchen, Germany; Iris Biotech GmbH, Marktredwitz, Germany; Orpegen, Heidelberg, Germany; ABCR, 
Karlsruhe, Germany; Alfa Aesar, Karlsruhe, Germany; Merk, Darmstadt; Germany and Acros, Geel, Belgien) 
and solvents (Fisher Scientific-Acros, Schwerte, Germany) were used without further purification. If necessary 
reactions were carried out under an atmosphere of argon or nitrogen and dry solvents. Analytical thin layer 
chromatography was carried out using aluminium-backed plates coated with Merck silica gel (60, F254). Analysis 
was performed by visualizing under UV light (λ = 254 nm) and by staining with KMnO4 solution (3 g KMnO4, 
20 g K2CO3, 300 ml dest. water, 5 ml NaOH solution (5 %)). Flash chromatography was carried out with 
Davisil® (Grace-Davison, Hollerhecke, Germany) silica gel (particle size 0.04-0.064 μm). Preparative HPLC was 
carried out on a 1260 Infinity (Agilent Technologies, Waldbronn, Germany) system with a C18 column 
212 x 250 mm, particle size 10 µm, Agilent Technologies, Waldbronn, Germany). 1H and 13C spectra were 
recorded at 298 K using Bruker Avance-II 400 MHz, Bruker Avance-III 500 MHz or Bruker Avance-III 
700 MHz instruments (Bruker, Karlsruhe, Germany). The chemical shifts are reported in ppm using the residual 
solvent peak as an internal reference (dmso-d6 or THF-d8). Multiplicity (bs = broad singlet, s = singlet, d = 
doublet, dd = doublet of doublet, t = triplet, q = quartet, m = multiplet) and coupling constants (J = Hz) are 
quoted where possible. HPLC-HRMS spectra were recorded on a QTrap LTQ XL (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) with an Agilent 1200 Series HPLC-System (Agilent Technologies, Waldbronn, 
Germany) with a C18 column (50 x 2 mm, particle size 3 µm). Optical rotation was determined with a P-2000 
Series system (Jasco Labor- und Datentechnik GmbH, Groß-Umstadt, Germany) with λ = 589 nm (sodium-D).  
CD spectra were recorded with a J-815 system (Jasco Labor- und Datentechnik GmbH, Groß-Umstadt, 
Germany). 
- wave length: λ = 250 - 400 nm 
- wave length interval: λ = 0.1 nm 
- scan speed: 100 nm/min 
- cell length: 10 mm 
- solvent and concentration: 0.25 mmol/L in DMSO (synthetic product, natural product not determined) 
Chiral HPLC was perfomed with a LaChrom system (Hitachi, Tokyo, Japan) with a Chiralpak® Daicel-
(polysaccharide-)column (250 x 4.6 mm, particle size 5 µm, Chiral Technologies Europe - Daicel Group, 
Illkirch, France). Gradient: (0.8 mL/min; 60 % to 66 % isopropanol in 15 min). IR spectroscopy was performed 
with a Jasco FT/IR-4100 system (Jasco Labor- und Datentechnik GmbH, Groß-Umstadt, Germany) as ATR. 
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Preparation of building block 2 
 
(E)-Allyl 3-(4-(allyloxy)phenyl)-2-methylacrylate (19):  
Compound 18[1] (1.00 eq, 9.30 mmol, 1.7 g) and K2CO3 (5.00 eq, 46.51 mmol, 6.4 g) were dissolved in DMF 
(15 mL) and allyl bromide (6.00 eq, 55.82 mmol, 4.8 mL) was added. The reaction mixture was stirred for 2 h at 
room temperature and diluted with EtOAc (100 mL). The mixture was washed with brine (3 x 100 mL), 5 % 
NaHCO3 solution (2 x 100 mL), brine (1 x 100 mL). The organic solvent was dried over Na2SO4, filtered and 
removed under reduced pressure. The product 19 was obtained after column chromatography (Si2O, hexane:ethyl 
acetate - 15:1) as a white solid (2.3 g, 94 %). 
TLC (hexane:ethyl acetate - 10:1): Rf = 0.64. 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 2.08 (s, 3H), 4.61 (d, J = 5.10 Hz, 2H), 4.68 (d, J = 5.37 Hz, 2H), 
5.23-5.29 (m, 2H), 5.34-5.43 (m, 2H), 6.95-6.10 (m, 2H), 7.02 (d, J = 8.87 Hz, 2H), 7.46 (d, J = 8.87 Hz, 2H), 
7.60 (s, 1H). 
13C-NMR (100 MHz, DMSO-d6): δ (ppm) = 13.9, 64.8, 68.2, 114.7, 117.6, 125.3, 127.7, 131.6, 132.9, 133.4, 
138.2, 158.5, 167.5. 
HRMS (ESI): m/z calculated C16H19O3+ [M+H]+ 259.1329, found 259.1329.  
IR (ATR) νmax (cm-1): 3081, 2985, 2925, 2867, 2321, 1702, 1603, 1509, 1301, 1246, 1177, 1120, 1021, 996, 926, 
833. 
(E)-3-(4-(Allyloxy)phenyl)-2-methylacrylic acid (2): 
Compound 19 (1.00 eq, 7.76 mmol, 2.0 g) was dissolved in THF (16 mL) and MeOH (18 mL). KOH (5.00 eq, 
38.79 mmol, 2.2 g) solved in H2O (16 mL) was added. The reaction mixture was stirred 12 h at room 
temperature and the organic solvent was removed under reduced pressure. The aqueous phase was acidified with 
5% HCl solution and the product was filtered. The product 2 was obtained after freeze drying as a white solid 
(1.6 g, 95 %). 
TLC (chloroform:methanol - 9:1): Rf = 0.55. 
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 2.04 (s, 3H), 4.62 (d, J = 5.15 Hz, 2H), 5.28 (d, J = 10.50 Hz, 1H), 
5.41 (d, J = 19.02 Hz, 1H), 6.02-6.09 (m, 1H), 7.02 (d, J = 8.72 Hz, 2H), 7.45 (d, J = 8.72 Hz, 2H), 7.55 (s, 1H), 
12.37 (bs, 1H). 
13C-NMR (100 MHz, DMSO-d6): δ (ppm) = 14.4, 68.7, 115.2, 118.1, 126.8, 128.6, 131.9, 124.0, 137.9, 158.8, 
170.0. 
HRMS (ESI): m/z calculated C13H13O3- [M-H]- 217.0859, found 217.0868.  
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IR (ATR) νmax (cm-1): 2911, 2859, 2621, 1827, 1673, 1602, 1509, 1418, 1248, 1180, 986, 940, 832, 535. 
Preparation of building block 3 
 
Boc-L-Cya-pABA-OtBu (7): 
Boc-L-Asn-OH 5 (2.00 eq, 2.07 mmol, 481 mg) and DCC (4.00 eq, 4.14 mmol, 854 mg) were dissolved in dry 
DMF (10 mL) under an atmosphere of argon and tert-butyl-4-aminobenzoat 6 (1.00 eq, 1.04 mmol, 200 mg) was 
added. The resulting suspension was stirred 18 h at room temperature and filtered (celite). The solution was 
diluted with EtOAc (40 mL) and washed with brine (3 x 25 mL), 5 % HCl solution (2 x 25 mL), sat. NaHCO3 
solution (2 x 25 mL), H2O (1 x 25 mL) and brine. The organic solvent was dried over Na2SO4 filtered and 
removed under reduced pressure. The product 7 was obtained after column chromatography (Si2O, hexane:ethyl 
acetate - 4:1) as a white solid (331 mg, 65 %). 
The enantiomer of 7 was synthesized in the same way and showed comparable analytical data (1H-, 13C-NMR 
and HRMS). 
chiral HPLC: ee = 96 % (0.8 mL/min; 60 % to 66 % isopropanol in 15 min, RT = 9.5 min). 
TLC (hexane:ethyl acetate - 2:1): Rf = 0.27. 
optical rotation (7)  = -35° (c = 1.00; MeOH); optical rotation (enantiomer)  = +42° (c = 0.80; 
MeOH). 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 1.40 (s, 9H), 1.53 (s, 9H), 2.83 (dd, J1 = 16.92 Hz, J2 = 9.13 Hz, 1H), 
2.99 (dd, J1 = 16.92 Hz, J2 = 5.10 Hz, 1H), 4.46 (dd, J1 = 13.70 Hz, J2 = 8.86 Hz, 1H), 7.58 (d, J = 7.79 Hz, 1H), 
7.71 (d, J = 8.60 Hz, 2H), 7.87 (d, J = 8.60 Hz, 2H), 10.48 (s, 1H). 
13C-NMR (100 MHz, DMSO-d6): δ (ppm) = 20.2, 27.8, 28.1, 51.4, 78.8, 80.3, 118.0, 118.7, 126.1, 130.1, 142.5, 
155.1, 164.5, 168.3. 
HRMS (ESI): m/z calculated C20H28N3O5+ [M+H]+ 390.2034, found 390.2017.  
IR (ATR) νmax (cm-1): 3351, 3278, 2983, 2932, 2268, 1704, 1686, 1603, 1508, 1409, 1298, 1247, 1159, 855, 770. 
HCl*H2N-L-Cya-pABA-OH (8): 
Compound 7 (1.00 eq, 6.40 mmol, 2.5 g) was dissolved in HCl/dioxane (25 mL, 4 M). The reaction mixture was 
stirred for 5 h at room temperature and the solvent was removed under reduced pressure. The product 8 was 
obtained as a white solid (1.7 g, quant.) and used in the next step without further purification.  
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The enantiomer of 8 was synthesized in the same way and showed comparable analytical data (HRMS). 
HRMS (ESI): m/z calculated C14H17NO4+ [M+H]+ 234.0873, found 234.0872. 
O2N-pABA-L-Cya-pABA-OH (3): 
Compound 8 (1.00 eq, 6.40 mmol, 1.7 g) was dissolved in dry DMF (25 mL) under an atmosphere of argon and 
triethylamine (5.00 eq, 31.99 mmol, 4.4 mL) was added. The activated ester O2N-pABA-OSu[2] 9 (2.00 eq, 
12.80 mmol, 3.4 g) was added and the reaction mixture was stirred 16 h at room temperature. The reaction 
mixture was diluted with EtOAc (100 mL) and washed with 5 % HCl solution (3 x 150 mL) and brine 
(1 x 150 mL). The organic solvent was dried over Na2SO4, filtered and removed under reduced pressure. The 
product 3 was obtained after column chromatography (Si2O, hexane:ethyl acetate - 1:1 to 0:1) as a white solid 
(2.2 g, 89 %). 
The enantiomer of 3 was synthesized in the same way and showed comparable analytical data (1H-, 13C-NMR 
and HRMS). 
TLC (chloroform:methanol - 9:0.5): Rf = 0.10.  
optical rotation  = -11° (c = 0.80; MeOH); optical rotation (enantiomer)  = +20° (c = 0.90; MeOH). 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 3.06 (dd, J1 = 16.92 Hz, J2 = 8.60 Hz, 1H), 3.17 (dd, J1 = 16.92 Hz, 
J2 = 5.37 Hz, 1H), 4.99-5.04 (m, 1H), 7.74 (d, J = 8.87 Hz, 1H), 7.92 (d, J = 8.87 Hz, 1H), 8.16 (d, J = 9.13 Hz, 
1H), 8.38 (d, J = 8.87 Hz, 1H), 9.53 (d, J = 7.79 Hz, 1H), 10.61 (s, 1H).  
13C-NMR (100 MHz, DMSO-d6): δ (ppm) = 21.0, 50.7, 118.0, 118.9, 123.6, 125.7, 129.1, 130.4, 139.0, 142.5, 
149.3, 165.1, 166.8, 167.6. 
HRMS (ESI): m/z calculated C18H15N4O6+ [M+H]+ 383.0986, found 383.0986.  
IR (ATR) νmax (cm-1): 3273, 3073, 2548, 2256, 1689, 1652, 1598, 1515, 1173, 1107, 851. 
Preparation of building block 4 
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2-(Allyloxy)-3-methoxy-4-nitrobenzaldehyde (11) 
Compound 10[3,4] (1.00 eq, 1.20 mmol, 237 mg) was dissolved in DMF (6 mL) and K2CO3 (2.00 eq, 2.41 mmol, 
332 mg) was added. Allyl bromide (1.50 eq, 1.80 mmol, 150 µL) was added and the reaction mixture was stirred 
for 23 h at room temperature. After dilution with EtOAc (20 mL) the mixture was washed with brine 
(3 x 20 mL). The organic layer was dried over MgSO4, filtered and the solvent was removed under reduced 
pressure. The product 11 was obtained after column chromatography (SiO2, hexane:ethyl acetate - 14:1) as a 
yellow oil (250 mg, 88 %). 
TLC (hexane:ethyl acetate - 10:1): Rf = 0.35. 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 3.95 (s, 3H), 4.71 (s, 2H), 5.29 (dd, J1 = 10.48 Hz, J2 = 1.61 Hz, 
1H), 5.41 (dd, J1 = 17.19 Hz, J2 = 1.34 Hz, 1H), 6.07-6.17 (m, 1H), 7.61 (d, J = 8.60 Hz, 1H), 7.74 (d, J = 8.33 
Hz, 1H), 10.28 (s, 1H). 
13C-NMR (100 MHz, DMSO-d6): δ (ppm) = 62.3, 75.7, 119.5, 119.9, 122.9, 133.0, 146.5, 148.3, 155.2, 189.1. 
HRMS (APCI): m/z calculated C11H12NO5+ [M+H]+ 238.0710, found 238.0709.  
IR (ATR) νmax (cm-1): 3088, 2950, 2873, 1695, 1591, 1471, 1349, 1259, 1208, 1030, 985, 813, 806. 
2-(Allyloxy)-3-methoxy-4-nitrobenzoic acid 
O2N-pMBA(Allyl)-OH (12) 
Compound 11 (1.00 eq, 6.88 mmol, 1.6 g) was dissolved in 2-methyl-2-butene (9 mL) and tBuOH (50 mL). 
NaClO2 (1.20 eq, 8.25 mmol, 930 mg, 80 %ig on mineral oil) dissolved in NaH2PO4-solution (8.5 mL, 0.5 M) 
was added and the reaction mixture was stirred for 5 h at room temperature. The reaction was quenched by the 
addition of Na2SO3 and the organic solvent removed under reduced pressure. After dilution with water the 
solution was acidified (5 % HCl) and the resulting solid was filtered. The product 12 was obtained after freeze 
drying as a white solid  without further purification (1.6 mg, 92 %). 
TLC (hexane:ethyl acetate - 10:1): Rf = 0.05. 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 3.90 (s, 3H), 4.57 (s, 2H), 5.24 (dd, 1H, J1 = 10.34 Hz, J2 = 1.48 Hz, 
1H), 5.37 (dd, J1 = 17.19 Hz, J2 = 1.61 Hz, 1H), 5.99-6.09 (m, 1H), 7.52 (d, J = 8.60 Hz, 1H), 7.67 (d, J = 8.60 
Hz, 1H). 
13C-NMR (100 MHz, DMSO-d6): δ (ppm) = 62.3, 75.1, 118.4, 119.2, 124.9, 132.4, 133.6, 146.2, 146.5, 151.6. 
HRMS (ESI): m/z calculated C11H10NO6- [M-H]- 252.0503, found 252.0507.  
IR (ATR) νmax (cm-1): 3096, 2951, 2870, 2688, 2581, 1890, 1695, 1589, 1525, 1415, 1353, 1305, 1244, 817. 
2-(Allyloxy)-3-methoxy-4-nitrobenzoic acid  
O2N-pMBA(Allyl)-OAllyl (20) 
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Compound 12 (1.00 eq, 0.91 eq, 230 mg) was dissolved in DMF (5 mL) and K2CO3 (2.00 eq, 1.82 mmol, 
250 mg) was added. Allyl iodide (1.50 eq, 1.36 mmol, 124 µL) was added and the reaction mixture was stirred 
for 3 h at room temperature. The reaction mixture was diluted with EtOAc (10 mL) and washed with brine 
(3 x 20 mL). The organic solution was dried over MgSO4, filtered and removed under reduced pressure. The 
product 20 was obtained after column chromatography (SiO2, hexane:ethyl acetate - 12:1) as a yellow oil 
(248 mg, 93 %). 
TLC (hexane:ethyl acetate - 10:1): Rf = 0.33. 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 3.92 (s, 3H), 4.56 (d, J = 5.91 Hz, 1H), 4.80 (d, J = 5.37 Hz, 1H), 
5.23-5.43 (m, 4H), 5.96-6.08 (m, 2H), 7.58 (d, J = 8.60 Hz, 1H), 7.71 (d, J = 8.60 Hz, 1H).  
13C-NMR (100 MHz, DMSO-d6): δ (ppm) = 62.7, 66.4, 75.6, 119.1, 119.2, 125.6, 131.2, 132.5, 133.7, 147.0, 
152.3, 164.4. 
HRMS (ESI): m/z calculated C14H16NO6 [M+H]+ 294.0972, found 294.0990.  
IR (ATR) νmax (cm-1): 3089, 2948, 1729, 1528, 1416, 1354, 1298, 1236, 1028, 989, 933, 819. 
Allyl 2-(Allyloxy)-4-amino-3-methoxybenzoate  
H-pMBA(Allyl)-OAllyl (13) 
Compound 20 (1.00 eq, 3.13 mmol, 916 mg) was dissolved in EtOH (30 mL) and SnCl2*2H2O (7.00 eq, 
21.88 mmol, 4.9 g) was added. The reaction mixture was stirred at 60 °C for 1 h and the solvent was removed 
under reduced pressure. The residue was dissolved in EtOAc (200 mL) and washed with saturated NaHCO3 
solution (3 x 200 mL) and brine (1 x 150 mL). The organic solvent was dried over Na2SO4, filtered and removed 
under reduced pressure. The product 13 was obtained after column chromatography (SiO2, hexane:ethyl acetate - 
8:1) as a yellow oil (703 mg, 86 %). 
TLC (hexane:ethyl acetate - 5:1): Rf = 0.27. 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 3.67 (s, 3H), 4.43 (d, J = 5.64 Hz, 2H), 4.64 (d, J = 5.37 Hz, 2H), 
5.16-5.23 (m, 2H), 5.31-5.37 (m, 2H), 5.77 (s, 2H), 5.93-6.10 (m, 2H), 6.44 (d, J = 8.60 Hz, 1H), 7.33 (d, J = 
8.60 Hz, 1H).  
13C-NMR (125 MHz, DMSO-d6): δ (ppm) = 60.1, 64.6, 74.7, 109.8, 111.3, 117.4, 117.9, 128.0, 133.7, 135.2, 
139.4, 148.0, 153.6, 165.0. 
HRMS (ESI): m/z calculated  C14H18NO4+ [M+H]+ 264.1230, found 264.1233.  
IR (ATR) νmax (cm-1): 3482, 3366, 2938, 1699, 1607, 1591, 1259, 1207, 1136. 
O2N- pMBA(Allyl)-pMBA(Allyl)-OAllyl (14) 
BTC (0.49 eq, 1.31 mmol, 388 mg) and the benzoic acid 12 (1.50 eq, 4.01 mmol, 1.0 g) were dissolved in dry 
THF (25 mL) under an atmosphere of argon. 2,4,6-Collidine (8.00 eq, 21.38 mmol, 2.8 mL) was added via 
S8 
 
syringe and the resulting suspension was stirred 15 min at room temperature. The amine 13 (1.00 eq, 2.67 mmol, 
703 mg) and DIPEA (10.00 eq, 26.72 mmol, 4.5 mL) were dissolved in dry THF (25 mL) under an atmosphere 
of argon and added to the suspension via syringe. The resulting solution was stirred 19 h at room temperature 
and the reaction was quenched by the addition of water. After removing the organic solvent the aqueous phase 
was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 100 mL), 
dried over Na2SO4, filtered and removed under reduced pressure. The product 14 was obtained after column 
chromatography (SiO2, hexane:ethyl acetate - 8:1) as a yellow oil (1.2 g, 91 %). 
TLC (hexane:ethyl acetate - 5:1): Rf = 0.26. 
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 3.90 (s, 3H), 3.99 (s, 3H), 4.53 (d, J = 4.53 Hz, 2H), 4.76 (d, J = 
4.76 Hz, 2H), 4.78 (d, J = 5.35 Hz, 2H), 5.23-5.30 (m, 3H), 5.37-5.44 (m, 3H), 6.00-6.13 (m, 3H), 7.57 (d, J = 
8.72 Hz, 1H), 7.74 (d, J = 8.72 Hz, 1H), 7.79 (d, J = 8.52 Hz, 1H), 8.21 (d, J = 8.72, 1H), 10.43 (s, 1H). 
13C-NMR (125 MHz, DMSO-d6): δ (ppm) = 61.6, 62.7, 65.6, 75.0, 75.9, 116.2, 118.3, 118.6, 119.8, 120.3, 
121.7, 125.4, 126.5, 133.1, 133.1, 133.8, 134.4, 136.4, 143.8, 146.5, 146.7, 150.9, 151.7, 162.9, 164.9. 
HRMS (ESI): m/z calculated  C25H27N2O9+ [M+H]+ 499.1711, found 499.1701. 
IR (ATR) νmax (cm-1): 3287, 3084, 2942, 1723, 1682, 1589, 1524, 1412, 1258. 
H- pMBA(Allyl)-pMBA(Allyl)-OAllyl (4) 
Compound 14 (1.00 eq, 14.86 mmol, 7.8 g) was dissolved in EtOH (250 mL) and SnCl2*2H2O (5.00 eq, 
74.27 mmol, 16.8 g) was added. The reaction mixture was stirred at 60 °C for 4 h and the solvent was removed 
under reduced pressure. The residue was dissolved in EtOAc (400 mL) and washed with saturated NaHCO3 
solution (3 x 300 mL) and brine (1 x 200 mL). The organic solvent was dried over Na2SO4, filtered and removed 
under reduced pressure. The product 4 was obtained after column chromatography (SiO2, hexane:ethyl acetate - 
3:1) as a yellow oil (6.7 g, 79 %). 
TLC (hexane:ethyl acetate - 3:1): Rf = 0.12. 
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 3.76 (s, 3H), 3.91 (s, 1H), 4.54 (d, J = 5.75 Hz, 2H), 4.76-4.79 (m, 
4H), 5.23-5.29 (m, 3H), 5.37-5.43 (m, 3H), 5.86 (s, 2H), 6.00-6.16 (m, 3H), 6.58 (d, J = 8.72 Hz, 1H), 7.54 (d, 
J = 8.92 Hz, 1H), 7.59 (d, J = 8.92 Hz, 1H), 8.36 (d, J = 8.92 Hz, 1H), 10.64 (s, 1H). 
13C-NMR (125 MHz, DMSO-d6): δ (ppm) = 60.1, 61.3, 65.5, 75.0, 110.7, 113.2, 114.9, 118.2, 118.5, 119.8, 
120.1, 126.8, 127.5, 133.2, 133.6, 134.5, 137.8, 138.1, 142.5, 148.0, 151.1, 151.6, 163.5, 165.0. 
HRMS (ESI): m/z calculated  C25H29N2O7+ [M+H]+ 469.1969, found 469.1958.  
IR (ATR) νmax (cm-1): 3501, 3368, 3316, 3196, 3081, 2986, 2931, 1877, 1702, 1592, 1526, 1265, 1133. 
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Synthesis of albicidin and its enantiomer 
 
 
O2N-pABA-L-Cya-pABA-pMBA(Allyl)-pMBA(Allyl)-OAllyl (15) 
BTC (0.49 eq, 1.31 mmol, 388 mg) and the benzoic acid 3 (1.00 eq, 2.61 mmol, 1.0 g) were dissolved in dry 
THF (10 mL) under an atmosphere of argon. 2,4,6-Collidine (2.67 eq, 6.96 mmol, 930 µL) was added via 
syringe and the resulting suspension was stirred 15 min at room temperature. The amine 4 (1.00 eq, 2.61 mmol, 
1.2 g) and DIPEA (10.00 eq, 26.72 mmol, 4.5 mL) were dissolved in dry THF (10 mL) under an atmosphere of 
argon and added to the suspension via syringe. After stirring the resulting solution for 3 h at room temperature 
two additional portions of activated benzoic acid 3 (1.00 eq, 2.61 mmol, 1.0 g) were added. The resulting 
solution was stirred 19 h at room temperature and the reaction was quenched with water. After removal of the 
organic solvent the aqueous phase was extracted with EtOAc (3 x 80 mL). The combined organic layers were 
washed with brine (1 x 200 mL), dried over Na2SO4, filtered and removed under reduced pressure. The product 
15 was obtained after column chromatography (SiO2, hexane:ethyl acetate - 1:1 to 0:1) as a yellow oil (1.2 g, 
91 %). 
The enantiomer of 15 was synthesized in the same way and showed comparable analytical data (1H-, 13C-NMR 
and HRMS). 
TLC (hexane:ethyl acetate - 5:1): Rf = 0.27.  
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optical rotation = +10° (c = 0.30; DMSO); optical rotation (enantiomer)  = -9° (c = 0.30; DMSO). 
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 3.09 (dd, J1 = 16.94 Hz, J2 = 8.82 Hz, 1H), 3.20 (dd, J1 = 16.84 Hz, 
J2 = 5.15 Hz, 1H), 3.93 (s, 3H), 3.94 (s, 3H), 4.55 (d, J = 5.75 Hz, 2H), 4.78 (d, J = 5.35 Hz, 2H), 4.81 (d, J = 
6.14 Hz, 2H), 5.04 (dd, J1 = 13.48 Hz, J2 = 8.13 Hz, 1H), 5.24-5.31 (m, 3H), 5.37-5.44 (m, 3H), 6.01-6.17 (m, 
3H), 7.58 (d, J = 8.72 Hz, 1H), 7.80-7.83 (m, 3H), 7.93 (d, J = 8.72 Hz, 1H), 8.00 (d, J = 8.72 Hz, 1H), 8.18 (d, 
J = 8.92 Hz, 1H), 8.34 (d, J = 8.72 Hz, 1H), 8.40 (d, J = 8.72 Hz, 1H), 9.54 (d, J = 7.73 Hz, 1H), 9.70 (s, 1H), 
10.62 (s, 1H), 10.66 (s, 1H).  
13C-NMR (125 MHz, DMSO-d6): δ (ppm) = 20.4, 51.2, 61.4, 61.5, 65.6, 75.0, 75.6, 115.3, 118.3, 118.6, 119.2, 
119.5, 120.0, 120.6, 120.8, 123.3, 124.1, 126.0, 126.8, 129.3, 129.4, 129.6, 131.9, 133.1, 133.2, 134.4, 137.0, 
139.5, 142.3, 143.0, 144.8, 149.8, 150.1, 151.6, 164.9, 165.3, 165.6, 168.1, 170.9. 
HRMS (ESI): m/z calculated  C43H41N6O12+ [M+H]+ 833.2777, found 833.2772.  
IR (ATR) νmax (cm-1): 3299, 2943, 1669, 1593, 1502, 1408, 1267. 
H-pABA-L-Cya-pABA-pMBA(Allyl)-pMBA(Allyl)-OAllyl (16) 
Compound 15 (1.00 eq, 2.07 mmol, 1.7 g) was dissolved in EtOH (50 mL) and SnCl2*2H2O (10.00 eq, 
20.65 mmol, 4.7 g) was added. The reaction mixture was stirred at 60 °C for 2 h and the solvent was removed 
under reduced pressure. The residue was dissolved in EtOAc (400 mL) and washed with saturated NaHCO3 
solution (3 x 300 mL) and brine (1 x 250 mL). The organic solvent was dried over Na2SO4, filtered and removed 
under reduced pressure. The product 16 was obtained after column chromatography (SiO2, chloroform:methanol 
- 9:0.3) as an orange solid (1.2 g, 73 %). 
The enantiomer of 16 was synthesized in the same way and showed comparable analytical data (1H-, 13C-NMR 
and HRMS). 
TLC (chloroform:methanol - 9:0.5): Rf = 0.20.  
optical rotation  = +32° (c = 0.30; DMSO); optical rotation (enantiomer)  = -28° (c = 0.30; DMSO) 
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 3.04 (dd, J1 = 16.84 Hz, J2 = 8.92 Hz, 1H), 3.12 (dd, J1 = 16.64 Hz, 
J2 = 5.55 Hz, 1H), 3.92 (s, 3H), 3.94 (s, 3H), 4.55 (d, J = 5.55 Hz, 2H), 4.78 (d, J = 5.35 Hz, 2H), 4.81 (d, J = 
6.14 Hz, 2H), 4.93 (dd, J1 = 17.64 Hz,  J2 = 8.13 Hz, 1H), 5.24-5.31 (m, 3H), 5.38-5.44 (m, 3H), 5.74 (s, 2H), 
6.01-6.17 (m, 3H), 6.58 (d, J = 8.52 Hz, 2H), 7.58 (d, J = 8.72 Hz, 1H), 7.67 (d, J = 8.52 Hz, 1H), 7.79-7-83 (m, 
3H), 7.93 (d, J = 8.72 Hz, 1H), 7.99 (d, J = 8.52 Hz, 1H), 8.34 (d, J = 8.92 Hz, 1H), 8.60 (d, J = 7.73 Hz, 1H), 
9.68 (s, 1H), 10.52 (s, 1H), 10.66 (s, 1H).  
13C-NMR (125 MHz, DMSO-d6): δ (ppm) = 20.4, 51.0, 61.4, 61.5, 65.6, 75.0, 75.6, 113.0, 115.3, 118.3, 118.8, 
119.2, 119.4, 120.4, 120.6, 120.8, 123.3, 126.0, 126.8, 129.3, 129.8, 133.1, 134.4, 137.0, 142.5, 143.0, 144.8, 
150.1, 151.6, 152.7, 162.9, 164.9, 165.3, 167.1, 169.1. 
HRMS (ESI): m/z calculated C43H43N6O10+ [M+H]+ 803.3035, found 803.3028.  
IR (ATR) νmax (cm-1): 3321, 2940, 2252, 1592, 1501, 1449, 1408, 1266. 
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Allyl-protected albicidin (17) 
BTC (1.15 eq, 0.37 mmol, 110 mg) and the benzoic acid 2 (3.50 eq, 1.12 mmol, 245 mg) were dissolved in dry 
THF (20 mL) under an atmosphere of argon. 2,4,6-Collidine (8.00 eq, 2.57 mmol, 350 µL) was added via 
syringe and the resulting suspension was stirred 15 min at room temperature. The amine 16 (1.00 eq, 0.32 mmol, 
258 mg) and DIPEA (10.00 eq, 3.21 mmol, 550 µL) were dissolved in dry THF (20 mL) under an atmosphere of 
argon and added to the suspension via syringe. The resulting solution was stirred 4 h at room temperature and the 
reaction was quenched with water. After removal of the organic solvent the aqueous phase was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with brine (1 x 30 mL), dried over Na2SO4, 
filtered and removed under reduced pressure. The product 17 was obtained after column chromatography (SiO2, 
chloroform:methanol - 1.8 % MeOH) as a white solid (320 mg, quant.). 
The enantiomer of 17 was synthesized in the same way and showed comparable analytical data (1H-, 13C-NMR 
and HRMS). 
TLC (chloroform:methanol - 9:0.5): Rf = 0.15. 
optical rotation = +26° (c = 0.30; DMSO); optical rotation (enantiomer)  = -26° (c = 0.30; DMSO). 
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 2.14 (s, 3H), 3.08 (dd, J1 = 16.75 Hz, J2 = 8.82 Hz, 1H), 3.17 (dd, J1 
= 16.84 Hz,  J2 = 5.35 Hz, 1H), 3.93 (s, 3H), 3.94 (s, 3H), 4.55 (d, J = 5.55 Hz, 2H), 4.63 (d, J = 5.15 Hz, 2H), 
4.78 (d, J = 5.35 Hz, 2H), 4.81 (d, J = 6.14 Hz, 2H), 5.00 (dd, J1 = 13.87 Hz,  J2 = 8.13 Hz, 1H), 5.25-5.32 (m, 
4H), 5.38-5.44 (m, 4H), 6.01-6.17 (m, 4H), 7.05 (d, J = 8.72 Hz, 2H), 7.32 (s, 1H), 7.46 (d, J = 8.72 Hz, 2H), 
7.58 (d, J = 8.72 Hz, 1H), 7.80-7.83 (m, 3H), 7.86 (d, J = 8.72 Hz, 2H), 7.93-7.95 (m, 3H), 8.00 (d, J = 8.72 Hz, 
2H), 8.34 (d, J = 8.72 Hz, 1H), 9.03 (d, J = 7.53 Hz, 1H), 9.69 (s, 1H), 10.15 (s, 1H), 10.59 (s, 1H), 10.66 
(s, 1H).  
13C(DEPTq)-NMR (175 MHz, DMSO-d6): δ (ppm) = 15.0, 20.5, 51.1, 61.4, 61.5, 65.6, 68.7, 75.3, 75.6, 115.2, 
118.1, 118.3, 118.6, 119.2, 119.4, 119.6, 120.6, 120.8, 123.3, 126.0, 126.8, 128.2, 128.7, 128.8, 129.3, 129.3, 
131.1, 131.6, 133.1, 133.2, 133.9, 134.0, 134.4, 137.0, 142.4, 143.0, 143.1, 144.8, 150.1 
HRMS (ESI): m/z calculated  C56H55N6O12+ [M+H]+ 1003.3873, found 1003.3880.  
IR (ATR) νmax (cm-1): 3284, 2926, 1646, 1592, 1502, 1449, 1405, 1244, 1179, 1120, 992, 922, 843. 
Albicidin (1a) 
Allyl protected albicidin 17 (1.00 eq, 0.13 mmol, 127 mg) was dissolved in dry THF (12 mL) under an 
atmosphere of argon and exclusion of light. Phenylsilane (8.00 eq, 1.01 mmol, 125 µL) and Pd[P(Ph)3]4 (0.50 eq, 
0.06 mmol, 73 mg) were added and the reaction mixture was stirred at room temperature for 16 h. The solvent 
was removed under reduced pressure and the product 1 was obtained after purification by RP-HPLC (20 
mL/min; 60 % to 90 % MeOH with 0.1 % TFA in 16 min; 100 % MeOH for 2 min, RT 9.5 min) as a white solid 
(28 mg, 26 %). 
Enantio-albicidin (1b) was synthesized in the same way and showed comparable analytical data (1H-, 13C-NMR 
and HRMS). 
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analyt. HPLC: tR = 8.89 min. 
optical rotation  = +23° (c = 0.30; DMSO); optical rotation (enantiomer)  = -19° (c = 0.30; DMSO). 
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 2.13 (s, 3H), 3.08 (dd, J1 = 16.94 Hz, J2 = 8.82 Hz, 1H), 3.15-3.19 
(m, 1H), 3.79 (s, 3H), 3.92 (s, 3H), 4.98-5.02 (m, 1H), 6.85 (d, J = 8.52 Hz, 2H), 7.28 (s, 1H), 7.36 (d, 
J = 8.32 Hz, 2H), 7.58 (d, J = 8.72 Hz, 2H), 7.80-8.04 (m, 10H), 9.02 (d, J = 7.53 Hz, 1H), 9.70 (s, 1H), 9.78 (s, 
1H), 10.12 (s, 1H), 10.59 (s, 1H), 11.16 (s, 1H), 11.53 (s, 1H).  
13C(DEPTq)-NMR (175 MHz, DMSO-d6): δ (ppm) = 15.0, 20.5, 40.5, 46.2, 51.1, 60.7, 61.0, 110.7, 115.4, 
115.9, 116.7, 118.7, 119.4, 119.6, 125.9, 126.1, 127.0, 127.9, 128.0, 128.1, 128.8, 129.2, 129.3, 130.0, 131.8, 
132.0, 134.4, 136.4, 136.6, 138.2, 140.7, 142.3, 143.2, 150.2, 154.9, 158.0, 163.8, 165.3, 166.6, 168.7, 169.3. 
HRMS (ESI): m/z calculated  C43H39N6O12- [M-H]- 841.2460, found 841.2440.  
IR (ATR) νmax (cm-1): 3285, 2924, 1648, 1599, 1415, 1276, 1133. 
Bioassay 
Minimal inhibitory concentration (MIC-values) 
The determination of the minimal inhibitory concentration (MIC-values) was performed by Antiinfectives 
Intelligence (Rheinbach, Germany) according to the standards for "antimicrobial disk and diulution susceptibility 
tests for bacteria isolated from animals; approved standard - second edition" (Clinical and Laboratory Standards 
Institute, M31-A2.)[5] 
 
Gyrase activity 
Gyrase supercoiling assays were performed in a total volume of 20 µl gyrase buffer (protocol by NEB, 
Frankfurt, Germany). The incubations contained 50 ng relaxed pUC19 plasmid DNA (NEB), 1 unit DNA-gyrase 
(2.2 nM) (NEB) and various concentrations of albicidin and enantioalbicidin (30-200 nM). Samples were 
incubated at 37 °C for 30 min and subsequently heated at 65 °C for 15 minutes to inactivate the gyrase. 
Electrophoretic analysis was performed on a 1% agarose gel. Staining of bands was performed with ethidium 
bromide. According to Hashimi et al. the IC50s were estimated as decribed in literature.[6] 
 Figure S 1. Inhibition assay of DNA gyrase supercoiling activity (
concentration (IC50) of ciproflaxacin (~200 nM). 
DNA (re), and the addition of enzyme (lane 0) results in supercoiled DNA (sc). The other lanes represent the reaction with 
enzyme and increasing concentrations of the corresponding drug 
Analytical Data 
Comparison of 1H- and 13C
Figure S 2. The chemical structure of albicidin and abbreviations regarding its building blocks.
Table S1: 1H and 13C chemical shifts of 
Multiplicities, scalar coupling constants 
  natural albicidin 
Position δ(1H) in ppm 
(multiplicity,integral,
in Hz) 
MCA1  
-/C1 - 
E. coli) for determination of the half maximal inhibitory 
The control experiment without enzyme and drug (lane c) shows relaxed 
(30-200 nM). 
-NMR data of natural and synthetic albicidin
 
natural and synthetic albicidin in d8-THF at 298
JHH and integrals are also given. 
synthetic albicidin 
 J 
δ(13C,) in ppm δ(1H) in ppm 
(multiplicity,integral, J 
in Hz) 
albicidin (syn.) 
  
168.3 (qC) - 
S13 
 
 
 
 K and 16.4 Tesla. 
δ(13C) in ppm 
 
 
168.3 (qC) 
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-/C2 - 130.0 (qC) - 131.00 (qC) 
H3/C3 7.30 (s, 1H) 133.5 (CH) 7.27 (s, 1H) 133.4 (CH) 
-/C4 - 127.3 (qC) - 127.4 (qC) 
H5/C5 7.33 (d, 2H, 8.8) 131.0(CH) 7.32 (d, 2H, 8.7) 131.1 (CH) 
H6/C6 6.84 (d, 2H, 8.5) 115.1 (CH) 6.82 (d, 2H, 8.5) 114.9 (CH) 
-/C7 - 157.9 (qC) - 157.4 (qC) 
OH @C7 n.d. - n.d. - 
H8/C8 2.20 (d, 3H,1.2) 13.7 (CH3) 2.19 (d, 3H, 1.2) 14.0 (CH3) 
pABA2     
/-C1 - 127.9 (qC) - 128.0 (qC) 
H2/C2 7.94 (d, 2H, 8.6) 128.2 (CH) 7.93 (d, 2H, 8.6) 128.0 (CH) 
H3/C3 7.89 (m, 2H)  118.8 (CH) 7.86 (m, 2H) 118.4 (CH) 
-/C4 - 143.3 (qC) - 143.0 (qC) 
NH @C4 9.37 (s, 1H) - 9.28 (s, 1H) - 
/-C5 - 166.9 (qC) - 166.7 (qC) 
Cya3     
NH 8.50 (d, 1H, 8.1) - 8.40 (d, 1H, 8.3) -  
Hα/Cα 5.16 (m, 1H) 50.8 (CH) 5.17 (m, 1.H) 52.6 (CH) 
Hβ’,Hβ’’/Cβ 3.13/3.07 (m, 2H) 19.5 (CH2) 3.10/3.00 (m, 2H) 19.8 (CH2) 
Cγ/Nδ
 
- 116.9 (qC) - 117.7 (qC)       
C’ - 167.8 (qC) - 168.6 (qC) 
pABA4     
-/C1 - 129.8 (qC) - 128.0 (qC) 
H2/C2 7.98 (d, 2H, 8.6) 128.2 (CH) 7.98 (d, 2H, 8.6) 128.0 CH 
H3/C3 7.88 (m, 2H)  118.9 (CH) 7.86 (m, 2H) 118.4 (CH) 
-/C4 - 142.3 (qC) - 142.5 (qC) 
NH @C4 10.09 (s, 1H) - 9.98 (s, 1H) - 
/-C5 - 164.2 (qC) - 163.8 (qC) 
pMBA5     
-/C1 - 114.1 (qC) - 114.1 (qC) 
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n.d. = not detected / ** reference signal for 1H integrals 
  
-/C2 - 151.3 (qC) - 151.6 (qC) 
OH @C2 n.d. - - n.d. 
-/C3 - 137.4 (qC) - 136.5 (qC) 
-/C4 - 136.7 (qC) - 137.1 (qC) 
NH @C4 9.03 (s, 1H) - 9.01 (s, 1H) - 
H5/C5 8.17 (d, 1H, 8.8) 111.3 (CH) 8.06 (d, 1H, 8.8) 109.9 (CH) 
H6/C6 7.81 (d, 1H, 8.8) 124.7 (CH) 7.70 (d, 1H, 8.8) 124.3 (CH) 
-/C7 - 165.3 (qC) - 165.8 (qC) 
H8/C8 
 
3.99 (s, 3H) 
 
60.0 (CH3) 
 
4.02 (s, 3H) 59.4 (CH3) 
 
 
pMBA6     
-/C1 - 109.1 (qC) - 113.0 (qC) 
-/C2 - 155.1 (qC) - 154.8 (qC) 
OH @C2 n.d. - n.d. - 
-/C3 - 136.7 (qC) - 137.3 (qC) 
-/C4 - 137.7 (qC) - 137.4 (qC) 
NH @C4 10.31/10.09 (s, 1H) - n.d. - 
H5/C5 8.13 (d, 1H, 8.8) 110.5 (CH) 8.18 (d, 1H, 8.8) 110.7 (CH) 
H6/C6 7.65 (d, 1H, 8.5) 125.3 (CH) 7.66 (d, 1H, 8.6) 125.3 (CH) 
-/C7 - 172.1 (qC) - 172.2 (qC) 
(CO)OH @C7 11.73 (s, 1H) - n.d. - 
H8/C8 4.04 (s, 3H)* 59.6 (CH3) 3.98 (s, 3H) 59.7 (CH3) 
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Comparison of MS/MS data of natural and synthetic albicidin 
Table S2. Conditions for MS2 experiments to compare the characteristic fragmentation of natural and synthetic 
albicidin 
 
 
 
Figure S 3. MS2 experiments of natural (A) and synthetic (B) albicidin with the resulting characteristic fragmentation 
pattern. Conditions are given in Table S2. 
  
Experiment Activation time Isolation window HCD collision energy R Mass range 
MS2 @ 843 30 ms 2.0 18 % 300000 100 - 1000 
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CD spectra 
The CD spectra were recorded of albicidin, its enantiomer and the natural product as described in general 
methods. 
 
Figure S 4. CD-spectra of albicidin, its enantiomer and the natural product. Detailed conditions are given in the gerneral 
section of the supporting information. 
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(E)-Allyl 3-(4-(allyloxy)phenyl)-2-methylacrylate (19): 
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 (E)-3-(4-(Allyloxy)phenyl)-2-methylacrylic acid (2): 
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 2-(Allyloxy)-3-methoxy-4-nitrobenzaldehyde (11) 
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 O2N-pMBA(Allyl)-OH (12) 
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 Allyl-protected albicidin (17) 
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 Albicidin (1a) 
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Chiral HPLC 
Boc- -Cya- ABA-O BuL p t
Boc- -Cya- ABA-O BuD p t
 
Figure S 5. Chiral HPLC chromatogram of Boc-L-Cya-pABA-OtBu and Boc-L-Cya-pABA-OtBu. The detailed conditions (column and gradient) are given in the general section of the supporting 
information.  
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